Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
Labetalol hydrochloride is a combined alpha and beta-adrenergic blocking agent approved as an intravenous solution for acute hypertension management. It is used primarily in hospital and acute care settings to rapidly lower blood pressure in hypertensive emergencies and perioperative hypertension. The drug works by competitively blocking both alpha-1 and beta-adrenergic receptors, reducing peripheral vascular resistance and cardiac output.
Peak lifecycle stage with moderate competitive pressure (30) indicates stable market position but requires active competitive monitoring and brand defense strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on labetalol hydrochloride offers career exposure in acute care/hospital pharmacy sales, a specialized but stable segment with strong relationships with ICU, OR, and obstetrics teams. The mature lifecycle and zero current clinical trials mean career growth centers on market defense, formulary strategy, and institutional partnerships rather than product development innovation.
Worked on LABETALOL HYDROCHLORIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo